147 related articles for article (PubMed ID: 21881536)
21. Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes.
Bolufer P; Sanz GF; Barragán E; Sanz MA; Cervera J; Lerma E; Senent L; Moreno I; Planelles MD
Haematologica; 2000 Dec; 85(12):1248-54. PubMed ID: 11114130
[TBL] [Abstract][Full Text] [Related]
22. The detection and significance of minimal residual disease in chronic myeloid leukemia.
Radich JP
Medicina (B Aires); 2000; 60 Suppl 2():66-70. PubMed ID: 11188935
[TBL] [Abstract][Full Text] [Related]
23. Molecular measurement of minimal residual disease in Philadelphia-positive acute lymphoblastic leukaemia.
Radich JP
Best Pract Res Clin Haematol; 2002 Mar; 15(1):91-103. PubMed ID: 11987918
[TBL] [Abstract][Full Text] [Related]
24. [Genetic diagnosis of chronic myeloid leukemia].
Kato C; Naoe T
Nihon Rinsho; 2001 Dec; 59(12):2336-41. PubMed ID: 11766335
[TBL] [Abstract][Full Text] [Related]
25. [Use of polymerase chain reaction (PCR) in oncohematology. Detection of minimal residual disease].
Kotliar N; Koziner B
Medicina (B Aires); 1995; 55(2):159-66. PubMed ID: 7565055
[TBL] [Abstract][Full Text] [Related]
26. Molecular diagnosis of the Philadelphia chromosome in chronic myelogenous and acute lymphoblastic leukemias by PCR.
Maurer J; Kinzel H; Nentwig T; Thiel E
Dis Markers; 1990; 8(4):211-8. PubMed ID: 2088636
[TBL] [Abstract][Full Text] [Related]
27. Monitoring of minimal residual disease in leukemia, advantages and pitfalls.
Cazzaniga G; Gaipa G; Rossi V; Biondi A
Ann Med; 2006; 38(7):512-21. PubMed ID: 17101542
[TBL] [Abstract][Full Text] [Related]
28. Detection of bcr/abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation.
Santini V; Zoccolante A; Bosi A; Guidi S; Saccardi R; Vannucchi AM; Martinazzo G; Bernabei PA; Ferrini PR
Haematologica; 1996; 81(3):201-7. PubMed ID: 8767524
[TBL] [Abstract][Full Text] [Related]
29. [Importance of quantitative evaluation of BCR-ABL transcripts using real-time PCR for effective treatment of chronic myeloid leukemia].
Beránek M; Voglová J; Sýkorová A; Belada D; Bláha M
Cas Lek Cesk; 2006; 145(1):25-9; discussion 29-30. PubMed ID: 16468238
[TBL] [Abstract][Full Text] [Related]
30. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
Xing W; Gu BW; Zhu YM; Jiang CL; Zhao RH; Wang AH; Sun HP; Li JM; Shen ZX; Chen Z; Chen SJ
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):453-7. PubMed ID: 15854550
[TBL] [Abstract][Full Text] [Related]
31. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
[TBL] [Abstract][Full Text] [Related]
32. Monitoring minimal residual disease in pediatric hematologic malignancies.
Campana D
Clin Adv Hematol Oncol; 2007 Nov; 5(11):876-7, 915. PubMed ID: 18185484
[No Abstract] [Full Text] [Related]
33. [The minimal residual disease (MRD) in hematological malignancies].
Yokota S; Okamoto T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):762-8. PubMed ID: 11432342
[TBL] [Abstract][Full Text] [Related]
34. Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation.
Martinelli G; Montefusco V; Testoni N; Amabile M; Saglio G; Ottaviani E; Terragna C; Bonifazi F; Rosti G; Bandini G; Tura S
Haematologica; 2000 Jun; 85(6):653-8. PubMed ID: 10870124
[TBL] [Abstract][Full Text] [Related]
35. [Molecular basis of chronic myelogenous leukemia and significance of diagnostic methods based on BCR-ABL gene amplification].
Sacha T; Dulak J; Skotnicki AB; Dembińska-Kiec A
Przegl Lek; 1999; 56 Suppl 1():57-61. PubMed ID: 10494184
[TBL] [Abstract][Full Text] [Related]
36. Detection of bcr-abl fusion mRNA in chronic myelogenous leukemia by reverse transcription polymerase chain reaction using nested primers.
Furukawa Y; Ju SL; Cho HL; Tatsumi N
Osaka City Med J; 1993 Jun; 39(1):35-45. PubMed ID: 7694218
[TBL] [Abstract][Full Text] [Related]
37. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
[TBL] [Abstract][Full Text] [Related]
38. Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay.
Goh HG; Lin M; Fukushima T; Saglio G; Kim D; Choi SY; Kim SH; Lee J; Lee YS; Oh SM; Kim DW
Leuk Lymphoma; 2011 May; 52(5):896-904. PubMed ID: 21338281
[TBL] [Abstract][Full Text] [Related]
39. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
[TBL] [Abstract][Full Text] [Related]
40. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]